Puma Biotechnology | PBYI - الأصول





الأصول تغيير تاريخ
Agios Pharmaceuticals USD 1.18B 112.24M 2026-03
Alnylam Pharmaceuticals USD 5.13B 163.22M 2026-03
Amgen USD 92.5B 1.92B 2026-03
Biogen USD 29.48B 43.6M 2026-03
BioMarin Pharmaceutical USD 8.59B 996.99M 2026-03
Daiichi Sankyo JPY 3.82T 252.52B 2025-12
Esperion Therapeutics USD 465.89M 101.87M 2025-12
Exelixis USD 2.84B 20.87M 2025-12
Gilead Sciences USD 59.02B 490M 2025-12
Glaxosmithkline GBP 82.34B 102.25M 2025-12
Incyte USD 7.34B 381.14M 2026-03
MacroGenics USD 256.85M 13.92M 2025-12
Moderna USD 11.49B 850M 2026-03
Novartis USD 118.53B 7.58B 2026-03
Pfizer USD 207.62B 542M 2026-03
PTC Therapeutics USD 2.9B 255.07M 2025-12
Puma Biotechnology USD 202.86M 7.95M 2025-09
Regeneron Pharmaceuticals USD 40.87B 310.1M 2026-03
Roche Holding CHF 100.7B 5.94B 2025-12
Sangamo BioSciences USD 97.56M 11.39M 2025-06
Sarepta Therapeutics USD 3.35B 143.73M 2025-12
Takeda JPY 15.41T 938.47B 2025-12
TG Therapeutics USD 1.06B 38.23M 2025-12
Ultragenyx Pharmaceutical USD 1.53B 341.56M 2025-12
Vanda Pharmaceuticals USD 488.95M 112.19M 2025-12
Vertex Pharmaceuticals USD 26.48B 841.4M 2026-03